Generics 5

Originals

Biosimilars

Medical devices

Nutraceuticals

Filters

Degarelix acetate manufacturers

5 products found

Filters

5 products found

degarelix acetate

Powder for solution for injection/infusion 80 mg, 120 mg

Dossier type
US CTD
Dossier status
Ready to file
Country of origin
United States
GMP approvals
FDA
Unavailable markets
Australia , United States
Comments
Available for non US/EU/Australia
Manufacturer #28190
This privately held company develops, manufactures, and commercializes high-quality, affordable generic pharmaceuticals globally. Their focus is on products with formulation challenges and first-to-market opportunities within the generic space. Key therapeutic areas include those requiring complex formulations like injectables, sterile ophthalmic, and dermal products. They specialize in solid oral dosage forms through partnerships with other manufacturing facilities. The company holds GMP certifications and has a track record of developing patented product formulations. Their main production facility in North America is equipped for multi-format packaging and end-product release testing, ensuring a seamless process from bulk manufacturing to finished goods.

Manufacturer usually replies in 7 days

degarelix acetate

Injection, lyophilized 80 mg, 120 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
EU GMP
Manufacturer #15176

Manufacturer usually replies in 5 days

degarelix acetate

Solution for injection 120 mg / 80 ml

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
EU GMP, WHO
Manufacturer #9406

Manufacturer usually replies in 8 days

Want to see all 5 products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription

Degarelix Acetate

Degarelix Acetate is a long-acting, synthetic peptide of the acetate class. It has gonadotrophin-releasing hormone antagonistic properties. It is also a potent GnRH receptor antagonist, that is used for the treatment of patients with advanced prostate cancer. Degarelix actions block gonadotrophin-releasing hormone receptors, which are situated on the surfaces of gonadotroph cells in the anterior pituitary. The blocking results in a reduction in the secretion of luteinizing hormone (LH) by pituitary gonadotroph cells and so decreasing testosterone production by interstitial cells in the testes. Degarelix Acetate is sold under the brand name Firmagon among others. The US Food and Drug Administration approved Degarelix in 2008, for the treatment of patients with advanced prostate cancer in the United States. By 2009, It was subsequently approved by the European Commission in 2009, for use in adult males with advanced, hormone-dependent prostate cancer.

Dosage and administration

Degarelix Acetate is available as in injection in 80gm and 120gm in a single vial. It is to be administered only subcutaneously and must not be administered intravenously. The usual adult dose, on which the treatment begins is set at a 240 mg given as two injections of 120 mg each. This is then followed by a maintenance doses of 80 mg, administered as a single injection every 28 days.

The cost of Degarelix Acetate

In the USA, the consumers have to pay around $519, for subcutaneous powder for injection of 80 mg for a supply of one powder for injection. This medicine is much cheaper in UK, whereht consumers have to pay an average retial price of £129.37, for subcutaneous powder for injection of 80 mg for a supply of one powder for injection.

How does Degarelix Acetate Work?

GnRH receptor blockers also called antagonists are synthetic peptide derivatives of the natural GnRH decapeptide. GnRH decapeptide is a hormone made by neurons in the hypothalamus. Degarelix Acetate competes with natural GnRH for binding to GnRH receptors in the pituitary gland. This binding blocks the release of LH and FSH from the pituitary and the blocking is reversible. LH reduction leads to a rapid and sustained suppression of testosterone release from the testicles. It also subsequently decreases the growth of the prostate cancer. The final result is a This reduction in prostate-specific antigen levels.

Finding Degarelix Acetate Manufacturers and Suppliers:

The process of finding trusted Degarelix Acetate manufacturers and Degarelix Acetate suppliers can be made quicker and more accessible by using Pipelinepharma's online the platform, a B2B marketplace that lets you finalize the deals of pharmaceutical products in a matter of a few clicks. Also, it is an easy to use an online platform to grow your business opportunities. The robust search engine makes it convenient to search for manufacturers and suppliers of Degarelix Acetate. The search can be further refined with industry-specific filters such as dossier type, country of origin, GMP approvals, and search criteria for Wholesaler, etc. helping to get in contact with the preferred manufacturer and supplier readily.

Interested in becoming a subscriber?

Please provide the following information to receive an offer tailored to your business needs

  1. Number of company users for the subscription
  2. The rough number of products you would like to source in the 12 months
  3. Target market(s) for commercialisation